Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Telangana, Johnson n...

    Telangana, Johnson n Johnson sign MoU to make state TB free

    Written by savita thakur thakur Published On 2016-10-16T09:47:36+05:30  |  Updated On 16 Oct 2016 9:47 AM IST
    Telangana, Johnson n Johnson sign MoU to make state TB free

    Hyderabad : The Telangana government has entered into an MoU with pharma, life sciences and healthcare multinational company Johnson & Johnson to work together for making the state tuberculosis free, it was announced here.


    The New Jersey-based Johnson & Johnson will play an active role in the project by assisting the state government in achieving the goal.


    The MoU was signed when Industries Minister K.T. Rama Rao called on top leadership of the company on the second day of his business visit to the US.


    Rama Rao met Paul Stoffel, Chief Scientific Officer and Chairman of Pharmaceuticals Division, Melinda Richter, Head of JLabs and Jonathan Collard, VP, Government Affairs and Policy, Asia Pacific.


    Stoffel was very enthusiastic about proposed Hyderabad Pharma City, and will be visiting India and Hyderabad next year, said a statement from the minister's office here.


    Richter assured the Telangana delegation that they would explore the possibility of setting up of JLabs unit in Hyderabad.


    Later, the minister met Sanat Chattopadhyay, Executive VP and President, Merck Manufacturing Division, who mentioned the firm's intent for a social partnership with Telangana Government on arresting infant diarrhoea.


    Merck also expressed interest in setting up manufacturing base in Telangana in collaboration with local partners. It also evinced interest in setting up "vaccine centre of excellence" in Hyderabad which will also be used for imparting skills, providing training based on the specific requirement of the companies.


    Nanette Cocero, President for Emerging Markets for Innovative Health business, Pfizer and Jeffery T. Hamilton, Senior Director, Pfizer, during their discussions with Minister explained about Pfizer's ECHO project in the area of breast cancer screening.


    The minister elaborated on the steps Telangana Government initiated to boost the pharma sector in Hyderabad and invited Pfizer to associate with Research and Innovation Circle of Hyderabad (RICH).


    Another MoU was signed with IV2 Alliance, a non-profit corporation and one that works in tandem with US Food and Drug Administration (USFDA) to promote collaboration within the scientific, research and provider communities to achieve advances in the field of healthcare and wellness.


    USFDA in a written communication stated that Pharma City near Hyderabad can be the first of the international clusters it seeks to bring together to link scientific and medical advances from across the globe for better healthcare.

    HealthcareJ&JJohnson & JohnsonMelinda RichterMoUNanette CoceroPaul StoffelPfizerPharma CityRama RaoSanat Chattopadhyaystate TB freeTuberculosisUS Food & Drug AdministrationUSFDA
    Source : IANS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok